Executive Appointments
Noom Strengthens Commercial Leadership Team with Trio of Executive Healthcare Appointments
March 07, 2024 08:03 ET | Noom Inc
Jodi Bryant joins as President, Healthcare, Matt Moran as Chief Strategy Officer, and Cody Fair elevated to Chief Commercial Officer at Noom.
DPP Noom
Noom Earns Highest CDC Recognition for Diabetes Prevention Program
March 05, 2024 08:47 ET | Noom Inc
The CDC Full Plus Recognition sets a new standard for digital health solutions providing metabolic health, chronic disease prevention, and weight loss.
July 30, 2021 - ROSEN LOGO.jpg
NATIONALLY RANKED ROSEN LAW FIRM Encourages Altimmune, Inc. Investors to Inquire About Securities Class Action Investigation – ALT
February 19, 2024 16:53 ET | The Rosen Law Firm PA
NEW YORK, Feb. 19, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Altimmune,...
tiziana-logo.png
Tiziana Life Sciences Files New Patent Application for Combination Therapy of anti-CD3 (Foralumab) with GLP-1 Receptor Agonist for Additional Reduction of Obesity - Associated Inflammation
January 05, 2024 07:00 ET | Tiziana Life Sciences Ltd.
Tiziana Life Sciences Files New Patent Application for Combination Therapy of anti-CD3 (Foralumab) with GLP-1 Receptor Agonist
zealand_logo_RGB_01.png
Zealand Pharma to highlight obesity pipeline at R&D Event on December 5
December 04, 2023 02:30 ET | Zealand Pharma
Press release – No. 16 / 2023 Zealand Pharma to highlight obesity pipeline at R&D Event on December 5 Event to be hosted by company management and feature key external scientific and...
Image 1
Evoke Pharma & EVERSANA Unveil Cost Savings Real-World Data Demonstrating Meaningfully Reduced Healthcare Costs for Patients Using GIMOTI Over Oral Metoclopramide Presented at the American College of Gastroenterology 2023
October 31, 2023 08:30 ET | Evoke Pharma, Inc.
SOLANA BEACH, Calif., Oct. 31, 2023 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with...
Telegenixx.png
Workplace Weight Loss & Wellness Program Unveiled
October 04, 2023 13:27 ET | Telegenixx
Telegenix's New Program Enables Employers to Provide Access to Pharma-Assisted Weight Loss at a Cost of $299 per Month, 70% Below the Industry Average
structure_inline_fullcolor_rgb_12in@300ppi.png
Structure Therapeutics Announces $300 Million Private Placement Equity Financing
September 29, 2023 07:32 ET | Structure Therapeutics Inc.
$300 million financing includes significant participation from a number of large healthcare dedicated institutional and mutual fund investors Net proceeds, along with existing cash, cash equivalents...
structure_inline_fullcolor_rgb_12in@300ppi.png
Structure Therapeutics Announces Positive Results from Phase 1b Clinical Study of Oral GLP-1 Receptor Agonist GSBR-1290 and Provides Program Update
September 29, 2023 07:30 ET | Structure Therapeutics Inc.
GSBR-1290 shown to be generally well-tolerated with no adverse event-related discontinuations in Phase 1b multiple ascending dose study Significant weight loss at 28 days supporting once-daily...
structure_inline_fullcolor_rgb_12in@300ppi.png
Structure Therapeutics Reports Second Quarter 2023 Financial Results and Recent Highlights
August 10, 2023 16:05 ET | Structure Therapeutics Inc.
Completed enrollment in 12-week Phase 2a study of oral GLP-1 receptor agonist, GSBR-1290 Topline data from Phase 2a and Phase 1b multiple ascending dose study of GSBR-1290 expected in latter half of...